Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1713
    +0.0019 (+0.16%)
     
  • GBP/USD

    1.2624
    +0.0002 (+0.01%)
     
  • Bitcoin GBP

    55,810.24
    +676.61 (+1.23%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,333.32
    +165.25 (+0.41%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

AstraZeneca Reports Promising Data for Lynparza in Ovarian Cancer

AstraZeneca Reports Promising Data for Lynparza in Ovarian Cancer

On June 27, AstraZeneca (AZN) and Merck (MRK) reported positive data for their Phase 3 Lynparza trial, SOLO-1, a randomized, double-blind, placebo-controlled trial for ovarian cancer. The drug met the primary endpoint of progression-free survival in women with BRCA1-mutated advanced ovarian cancer. Lynparza is the only PARP2 inhibitor to show significant activity in a first-line maintenance setting. Based on this data, the two companies plan to initiate discussions with authorities for regulatory submissions.